CTRI/2023/06/053922
Completed
Phase 2
A clinical study to evaluate the efficacy of the test products in improving hair growth & hair fall reduction.
Hindustan Unilever Ltd0 sites216 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Hindustan Unilever Ltd
- Enrollment
- 216
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Male and female volunteers in general good health with mild to moderate hair fall
- •2\. Volunteers in the age group 18\-50 years (both the ages inclusive).
- •3\. Volunteers willing to give a written informed consent and agree to come for a regular follow up visit.
- •4\. Volunteers willing to abide by and comply with the study protocol.
- •5\. Volunteers who have not participated in a similar investigation in the past three months.
- •6\. Volunteers with no known allergy as established by medical history.
- •7\. Volunteers who do not smoke or drink alcohol.
- •8\. Volunteers who are not crash dieting.
- •9\. Volunteers who agree to refrain from using hair dye / hair colour during the study period.
- •10\. Volunteers willing to refrain from any type of hair treatment like perming, straightening etc. during the study duration.
Exclusion Criteria
- •1\. Volunteers who have undergone hair growth treatment within 3 months before screening into the study.
- •2\. Volunteers having any active scalp disease which may interfere in the study dermatologist’s judgement.
- •3\. Volunteers who have taken chemotherapy for cancer in the 6 months prior to start of the study or have a plan to do treatments during study.
- •4\. Volunteers who have history of alcoholism and/ or psychiatric disorder including trichotillomania.
- •5\. Volunteers who have had hair transplants.
- •6\. Volunteers who take pharmaceutical product which cause hirsutism (ex. phenytoin) and finesteride for androgenic alopecia.
- •7\. A known history or present condition of allergic response/hypersensitivity to any cosmetic ingredients and pharmaceutical products.
- •8\. Volunteers consuming alcohol and smoking
- •9\. Volunteers on oral medications which will compromise the study.
- •10\. Volunteers who are pregnant or lactating or nursing as established with medical history.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A clinical study for evaluating the efficacy of the highly-concentrated oxygen nanobubble water -immune function, fatigue, autonomic nervous function and skin functionJPRN-UMIN000018755Soiken Inc.17
Not yet recruiting
Phase 3
Shirishadi Malhar & Parushakadi Yog in the Management of KIKKISA w.s.r. to STRIAE GRAVIDARUMHealth Condition 1: L929- Granulomatous disorder of the skinand subcutaneous tissue, unspecifiedHealth Condition 2: L99- Other disorders of skin and subcutaneous tissue in diseases classified elsewhereCTRI/2023/07/055029Government of Himachal Pradesh
Completed
Not Applicable
A clinical study for evaluating the efficacy of test food on the suppression of the elevation of postprandial blood glucose level. -Randomised double-blind placebo-controlled trialHealthy adultJPRN-UMIN000035336KSO Corporation50
Completed
Not Applicable
A clinical study for evaluating the efficacy of test food on the suppression of the elevation of postprandial blood glucose levelHealthy adultJPRN-UMIN000043321Pharma Foods International Co., Ltd.30
Completed
Not Applicable
A clinical study for evaluating the efficacy of test food on the suppression of the elevation of postprandial serum triglyceride. : Randomised double-blind placebo-controlled trialHealthy adultJPRN-UMIN000036241Allegro Inc.30